Meyka Pro banner
JW (Cayman) Therapeutics Co. Ltd

JW (Cayman) Therapeutics Co. Ltd (2126.HK) Stock Competitors & Peer Comparison

See (2126.HK) competitors and their performances in Stock Market.

2126.HKHKSE
HealthcareBiotechnology
HK$1.67
HK$0.05(2.91%)
Hong Kong Market is Open · 14:20

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2126.HKHK$1.68-2.33%699.7M-1.10-HK$1.52N/A
4332.HKHK$1,850.00+0.00%998.5B45.81HK$40.38N/A
6160.HKHK$196.50+1.81%265B88.84HK$2.21N/A
2269.HKHK$38.84+0.05%160.9B30.39HK$1.28N/A
1801.HKHK$92.25+0.11%160.6B169.64HK$0.54N/A
6990.HKHK$517.00+1.08%120.6B-256.32-HK$2.02N/A
9926.HKHK$98.90+4.55%91B-73.72-HK$1.34N/A
3347.HKHK$38.16+1.65%46.3B39.06HK$0.98+0.39%
1530.HKHK$17.29+2.19%43.2B4.50HK$3.84+1.48%
6821.HKHK$118.90-2.86%42.9B38.98HK$3.05+1.22%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2126.HK vs 4332.HK Comparison July 2026

2126.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2126.HK stands at 699.7M. In comparison, 4332.HK has a market cap of 998.5B. Regarding current trading prices, 2126.HK is priced at HK$1.68, while 4332.HK trades at HK$1,850.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2126.HK currently has a P/E ratio of -1.10, whereas 4332.HK's P/E ratio is 45.81. In terms of profitability, 2126.HK's ROE is -0.75%, compared to 4332.HK's ROE of N/A. Regarding short-term risk, 2126.HK is more volatile compared to 4332.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2126.HK.Check 4332.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions